Showing results (51-60 of 447) with videos related to
Sort By:
Pageof 45
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2022
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLCRyoko Inaba Higashiyama, Tatsuya Yoshida, Shigehiro Yagishita, et al.Journal for Immunotherapy of Cancer|June 29, 2026
Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancerRyoko Inaba Higashiyama, Tatsuya Yoshida, Shigehiro Yagishita, et al.European Journal of Cancer (Oxford, England : 1990)|December 22, 2021
Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancerMasayuki Shirasawa, Tatsuya Yoshida, Tatsuya Imabayashi, et al.Anticancer Research|January 25, 2023
Real-world Data on the Incidence of Coronavirus Disease (COVID-19) in Patients With Advanced Thoracic Cancer During the Early Phase of the Pandemic in JapanAkito Fukuda, Tatsuya Yoshida, Shigehiro Yagishita, et al.Lung Cancer (Amsterdam, Netherlands)|April 9, 2024
Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expressionJun Miyakoshi, Tatsuya Yoshida, Jumpei Kashima, et al.Japanese Journal of Clinical Oncology|June 6, 2023
Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistanceTaisuke Araki, Shintaro Kanda, Hidehito Horinouchi, et al.BMC Medical Informatics and Decision Making|February 18, 2025
A series of natural language processing for predicting tumor response evaluation and survival curve from electronic health recordsToshiki Takeuchi, Hidehito Horinouchi, Ken Takasawa, et al.European Journal of Clinical Pharmacology|January 18, 2022
Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitantHideyuki Hibino, Naomi Sakiyama, Yoshinori Makino, et al.Clinical Therapeutics|January 18, 2016
Pharmacokinetics of Weekly Paclitaxel and Feasibility of Dexamethasone Taper in Japanese Patients with Advanced Non-small Cell Lung CancerHiroshi Nokihara, Noboru Yamamoto, Yuichiro Ohe, et al.Thoracic Cancer|October 4, 2022
End-of-life impact of concurrent diabetes mellitus and adrenal insufficiency as immune-related adverse events in an advanced non-small cell lung cancer patientTomoaki Nakamura, Yuki Takeyasu, Tatsuya Yoshida, et al.Pageof 45